Sign In
Buy AMRX
$18.09
+0.170 (+0.95%)
At Close: Jul 27, 2026
Amneal Pharmaceuticals (AMRX) Beats Q3 Earnings and Revenue Estimates
08:16am, Thursday, 30'th Oct 2025
Amneal Pharmaceuticals (AMRX) came out with quarterly earnings of $0.17 per share, beating the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.16 per share a year ago.
Amneal Reports Third Quarter 2025 Financial Results
06:00am, Thursday, 30'th Oct 2025
‒ Q3 2025 Net Revenue of $785 million ; GAAP Net Income of $2 million ; Diluted Income per Share of $0.01 ‒ ‒ Adjusted EBITDA of $160 million ; Adjusted Diluted EPS of $0.17 ‒ ‒ Updated 2025
Amneal Receives U.S. FDA Tentative Approval for Beclomethasone Dipropionate HFA Inhalation Aerosol
04:05pm, Wednesday, 29'th Oct 2025
BRIDGEWATER, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has tentatively a
BRIDGEWATER, N.J., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced the U.S. commercial launch of Brekiya® (dihydroerg
Allspring Global Investments Holdings LLC Buys 13,187 Shares of AMNEAL PHARMACEUTICALS, INC. $AMRX
03:47am, Friday, 24'th Oct 2025
Allspring Global Investments Holdings LLC boosted its stake in AMNEAL PHARMACEUTICALS, INC. (NASDAQ: AMRX) by 21.8% during the undefined quarter, according to its most recent Form 13F filing with the
Analysts Estimate Amneal Pharmaceuticals (AMRX) to Report a Decline in Earnings: What to Look Out for
11:05am, Thursday, 23'rd Oct 2025
Amneal (AMRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Are Investors Undervaluing Amneal Pharmaceuticals (AMRX) Right Now?
10:41am, Tuesday, 07'th Oct 2025
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Take the Zacks Approach to Beat the Markets: Amneal Pharmaceuticals, Leidos & Vishay Precision in Focus
09:11am, Monday, 06'th Oct 2025
Amneal Pharmaceuticals, Leidos and Vishay Precision stand out as Zacks highlights amid market volatility and shifting rate expectations.
Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year?
10:41am, Thursday, 02'nd Oct 2025
Here is how Amneal Pharmaceuticals (AMRX) and ANIXA BIOSCIENCES INC (ANIX) have performed compared to their sector so far this year.
3 Lesser-Known Healthcare Names With Major Upside in Store
08:19am, Thursday, 02'nd Oct 2025
The global healthcare market is growing rapidly—it is expected to climb at a 6.9% CAGR over the next eight years, reaching more than $22.3 trillion by 2033. Its appeal to investors in the current ma
Amneal to Report Third Quarter 2025 Results on October 30, 2025
04:05pm, Tuesday, 30'th Sep 2025
BRIDGEWATER, N.J., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (NASDAQ: AMRX) (“Amneal” or the “Company”), a global biopharmaceutical company, today announced that the Comp
Amneal Announces BLA Submission of Biosimilar Candidate to XOLAIR® (omalizumab)
08:00am, Friday, 26'th Sep 2025
Potential first-wave entry into the $4+ billion U.S. market and an important new growth driver for Amneal Potential first-wave entry into the $4+ billion U.S. market and an important new growth driver
Amneal Receives U.S. FDA Approval for Bimatoprost Ophthalmic Solution, 0.01%
08:00am, Tuesday, 23'rd Sep 2025
BRIDGEWATER, N.J., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has approved the
Amneal Receives U.S. FDA Approval of Sodium Oxybate Oral Solution
08:00am, Thursday, 11'th Sep 2025
BRIDGEWATER, N.J, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) today announced the U.S. Food and Drug Administration (FDA) approval of Amneal's s
Amneal Pharmaceuticals: A Large, Diversified Clinical Portfolio That Keeps Growing
07:23am, Thursday, 11'th Sep 2025
For my initial rating of Amneal Pharmaceuticals (AMRX), I am calling it a buy. I was impressed by its large, diversified portfolio of therapies across clinical segments, and active pipeline of future
